Belize vs Maldives: Share of the population living with HIV receiving antiretroviral therapy
Belize
49.6%
in 2024
Maldives
48.5%
in 2024
Belize rank
127th
Maldives rank
129th
Share of the population living with HIV receiving antiretroviral therapy over time
- Belize
- Maldives
How they compare
Belize currently reports 49.6% against 48.5% in Maldives, a difference of 1.1%.
The two have swapped places 5 times across 35 shared years of data; in 1990 it was Maldives ahead.
Belize ranks 127th and Maldives ranks 129th of 149 countries.
Across the 4 decades both report, Belize averaged higher in 2 and Maldives in 1.
Head to head by decade
| Decade | Belize | Maldives | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | — |
| 2000s | 10.0% | 21.1% | 11.1% | Maldives |
| 2010s | 34.9% | 24.9% | 10.0% | Belize |
| 2020s | 44.8% | 43.7% | 1.1% | Belize |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Belize or Maldives?
- Belize, at 49.6% against 48.5% in Maldives as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Belize and Maldives?
- 1.1%, with Belize ahead.
- How many years of comparable data are there for Belize and Maldives?
- 35 years are reported by both, from 1990 to 2024.
- How do Belize and Maldives rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Belize ranks 127th and Maldives ranks 129th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.